Gemcitabine in Combination With Doxorubicin in Advanced Breast Cancer: Final Results of a Phase II Pharmacokinetic Trial
- 1 July 2000
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (13) , 2545-2552
- https://doi.org/10.1200/jco.2000.18.13.2545
Abstract
PURPOSE: Gemcitabine has promising single-agent activity in advanced breast disease. The aim of this phase II study was to determine the efficacy, toxicity, and pharmacokinetic profile of gemcitabi...Keywords
This publication has 29 references indexed in Scilit:
- 664: Phase II study of gemcltablne in patients with metastatic breast cancerEuropean Journal Of Cancer, 1997
- Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II studyEuropean Journal Of Cancer, 1996
- Cancer statistics, 1996CA: A Cancer Journal for Clinicians, 1996
- Phase II study of gemcitabine in patients with advanced pancreatic cancerBritish Journal of Cancer, 1996
- Safety profile of gemcitabineAnti-Cancer Drugs, 1995
- Gemcitabine in advanced breast cancerAnti-Cancer Drugs, 1995
- Advanced breast cancer: a phase II trial with gemcitabine.Journal of Clinical Oncology, 1995
- Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer PatientsJNCI Journal of the National Cancer Institute, 1994
- Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC)Annals of Oncology, 1994
- Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreasInvestigational New Drugs, 1994